Evicenter
P&T meetings

Emcitate (tiratricol)

MCT8 deficiency

Last updated
78 sources

Product information and disease descriptionProduct descriptionProduct information

Co-prescribed/Concomitant therapies

2 evidence topics · 3 sources

Other thyroid medications

“Taking EMCITATE in combination with thyromimetic products or products used to treat thyroid conditions (e.g., levothyroxine, propylthiouracil, and carbimazole) may increase the risk of thyrotoxicosis or hypothyroidism and should be avoided.” (opens the prescribing information at this quote)

“Patients taking another thyroid medication should talk to their healthcare provider before starting Emcitate, as the two should not be used together.” (opens the source at this quote in a new tab)

“Conventional antithyroid drugs such as carbimazole or methimazole are not recommended in MCT8 deficiency, as the thyrotoxic state is not driven by primary TH overproduction, and their use may exacerbate central hypothyroidism.” (opens the source at this quote in a new tab)

Concomitant hepatotoxic medications

“These patients often receive concomitant medications, some of which have known hepatotoxic side effects. In an open-label clinical trial, 25 of 46 patients (54%) treated with TRIAC showed mild increases in ALT, aspartate aminotransferase, or γ-glutamyl transferase at baseline, attributed to concurrent use of hepatotoxic medications. Therefore, liver function assessment is an important parameter to evaluate before and during therapy initiation, particularly when patients receive potentially hepatotoxic medications, such as anticonvulsants” (opens the source at this quote in a new tab)